| P2093 | author name string | Sture Lindegren | |
| | Lars Gedda | |
| | Lovisa Göstring | |
| P2860 | cites work | Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90 | Q28143497 |
| | The deaf and the dumb: the biology of ErbB-2 and ErbB-3 | Q28185247 |
| | ErbB2 degradation mediated by the co-chaperone protein CHIP | Q28208008 |
| | Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 |
| | Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin | Q30839490 |
| | Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold | Q33330736 |
| | 125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts | Q36198091 |
| | Down regulation of epidermal growth factor receptors: direct demonstration of receptor degradation in human fibroblasts | Q36210313 |
| | Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors | Q36720680 |
| | Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study. | Q36999363 |
| | Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin | Q37081037 |
| | A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer | Q37338986 |
| | Engineered affinity proteins for tumour-targeting applications | Q37430356 |
| | Geldanamycin and its anti-cancer activities | Q37619906 |
| | Chemical and radiochemical considerations in radiolabeling with α-emitting radionuclides. | Q37971505 |
| | Association with membrane protrusions makes ErbB2 an internalization-resistant receptor | Q38345553 |
| | Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. | Q39943343 |
| | A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells | Q39943622 |
| | An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models | Q40025393 |
| | Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. | Q40274520 |
| | Geldanamycin stimulates internalization of ErbB2 in a proteasome-dependent way. | Q40340333 |
| | Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. | Q40748731 |
| | ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. | Q40966152 |
| | The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. | Q41469562 |
| | Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation | Q42800575 |
| | Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate | Q46429197 |
| | Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. | Q54667220 |
| | Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. | Q54673289 |
| | Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects | Q73075684 |
| | Radiation doses to the cell nucleus in single cells and cells in micrometastases in targeted therapy with (131)I labeled ligands or antibodies | Q73516010 |
| | Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma | Q85074832 |
| P433 | issue | 4 | |
| P304 | page(s) | 2574-2580 | |
| P577 | publication date | 2016-08-10 | |
| P1433 | published in | Oncology Letters | Q20640514 |
| P1476 | title | 17AAG-induced internalisation of HER2-specific Affibody molecules | |
| P478 | volume | 12 | |